LEGN — Legend Biotech Corporation

Is LEGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Legend Biotech Corporation (LEGN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $15.99. The rating moved from Overbought to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Legend Biotech is positioned to benefit from commercial adoption of its lead cell therapy and a strong commercialization partner that gives distribution and payer reach. Near‑term catalysts include continued Carvykti sales growth, additional label or line‑extension data readouts, and ongoing manufacturing scale improvements that can relieve supply constraints and convert demand into revenue. Key challenges are execution on manufacturing, reimbursement negotiation, and intensifying competition from bispecifics and other cell therapies. Given the current market backdrop—measured risk‑on tone and defensive interest in healthcare—short‑term sentiment is supportive but volatility remains likely around clinical, safety or reimbursement news. Overall upside is driven by execution and readouts; downside is tied to supply disruption, regulatory setbacks, or adverse payer decisions.

Key factors

  • Commercial traction of Carvykti in relapsed/refractory multiple myeloma with growing real‑world uptake supporting revenue visibility
  • Strategic commercialization partnership with Janssen (J&J) provides scale, payer access and marketing resources
  • Pipeline potential and label expansion opportunities (earlier lines, combination studies) that could materially expand addressable market
  • Manufacturing scale‑up and CMC improvements underway that can improve supply reliability and margins if executed
  • Limited near‑term macro/geopolitical shocks and defensive sector flows into healthcare provide a supportive market backdrop for biotech execution

Risks

  • Execution risk on manufacturing scale and supply continuity for autologous/allogeneic cell therapies
  • Reimbursement and pricing pressure from payors, particularly given increasing scrutiny of high-cost specialty therapies
  • Competitive threats from bispecific antibodies and other CAR‑T entrants that could reduce uptake or pricing power
  • Regulatory or safety setbacks (label changes, adverse event reports) that could slow adoption
  • Capital markets volatility and investor sentiment shifts that disproportionately impact smaller biotech equities
  • Policy/antitrust or healthcare reform that indirectly affects access, reimbursement or distribution channels

See today's live rating, score and targets

Members see the live hourly rating for LEGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.